Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
22.12 (1y: +0%)
Market Cap 852.18 M P/E(ttm) 59.20
Enterprise Value 775.47 M P/B 6.20
ABMD- NAS (USA)
Abiomed, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$22.12
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry		 vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 382.22   Max: No Debt
Current: No Debt
Equity to Asset 0.806
ABMD's Equity to Asset is ranked higher than
85% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ABMD: 0.806 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.93
Current: 0.81
0.79
0.93
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
81% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 14.99
M-Score: -2.87
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 10.50
ABMD's Operating margin (%) is ranked higher than
79% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ABMD: 10.50 )
ABMD' s 10-Year Operating margin (%) Range
Min: -91.7   Max: 10.5
Current: 10.5
-91.7
10.5
Net-margin (%) 9.5
ABMD's Net-margin (%) is ranked higher than
83% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. ABMD: 9.5 )
ABMD' s 10-Year Net-margin (%) Range
Min: -80.7   Max: 9.5
Current: 9.5
-80.7
9.5
ROE (%) 11
ABMD's ROE (%) is ranked higher than
81% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ABMD: 11 )
ABMD' s 10-Year ROE (%) Range
Min: -43.7   Max: 11
Current: 11
-43.7
11
ROA (%) 8.8
ABMD's ROA (%) is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABMD: 8.8 )
ABMD' s 10-Year ROA (%) Range
Min: -37.5   Max: 8.8
Current: 8.8
-37.5
8.8
ROC (Joel Greenblatt) (%) 85.30
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. ABMD: 85.30 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -353.7   Max: 85.3
Current: 85.3
-353.7
85.3
Revenue Growth (%) 13.5
ABMD's Revenue Growth (%) is ranked higher than
95% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 13.5 )
ABMD' s 10-Year Revenue Growth (%) Range
Min: -3.5   Max: 13.5
Current: 13.5
-3.5
13.5
ยป ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ABMD Guru Trades in Q2 2012

Paul Tudor Jones 23,600 sh (+116.51%)
RS Investment Management 887,980 sh (+72.02%)
Jim Simons 243,023 sh (+30.43%)
PRIMECAP Management 5,006,690 sh (-0.17%)
Pioneer Investments 373,372 sh (-23.32%)
» More
Q3 2012

ABMD Guru Trades in Q3 2012

Steven Cohen 18,060 sh (New)
Pioneer Investments 497,960 sh (+33.37%)
Paul Tudor Jones 31,100 sh (+31.78%)
PRIMECAP Management 5,006,690 sh (unchged)
Jim Simons 221,223 sh (-8.97%)
RS Investment Management 491,180 sh (-44.69%)
» More
Q4 2012

ABMD Guru Trades in Q4 2012

Paul Tudor Jones 39,100 sh (+25.72%)
Pioneer Investments 563,603 sh (+13.18%)
Jim Simons 234,323 sh (+5.92%)
PRIMECAP Management 5,297,690 sh (+5.81%)
RS Investment Management Sold Out
Steven Cohen 1,000 sh (-94.46%)
» More
Q1 2013

ABMD Guru Trades in Q1 2013

Steven Cohen 18,973 sh (+1797.3%)
PRIMECAP Management 5,751,990 sh (+8.58%)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Pioneer Investments 437,683 sh (-22.34%)
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2011-06-30 Add 28.42%0.02%$14.65 - $18.94 $ 22.1232%3772973
PRIMECAP Management 2010-06-30 Add 20.11%0.01%$8.61 - $10.15 $ 22.12132%2551673
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 58.70
ABMD's P/E(ttm) is ranked lower than
58% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 22.90 vs. ABMD: 58.70 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 58.7
36.46
946.92
P/B 6.20
ABMD's P/B is ranked lower than
62% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABMD: 6.20 )
ABMD' s 10-Year P/B Range
Min: 0.85   Max: 8.99
Current: 6.2
0.85
8.99
P/S 5.70
ABMD's P/S is ranked lower than
58% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABMD: 5.70 )
ABMD' s 10-Year P/S Range
Min: 2.16   Max: 27.02
Current: 5.7
2.16
27.02
PFCF 37.90
ABMD's PFCF is ranked higher than
51% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. ABMD: 37.90 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 37.9
23.56
2462
EV-to-EBIT 45.5
ABMD's EV-to-EBIT is ranked lower than
58% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. ABMD: 45.5 )
ABMD' s 10-Year EV-to-EBIT Range
Min: 27   Max: 694.7
Current: 45.5
27
694.7

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 19.2
ABMD's Price/Net Cash is ranked lower than
57% of the 90 Companies
in the Global Medical Devices industry.

( Industry Median: 10.50 vs. ABMD: 19.2 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.7   Max: 30.6
Current: 19.2
1.7
30.6
Price/Net Current Asset Value 32.7
ABMD's Price/Net Current Asset Value is ranked lower than
52% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. ABMD: 32.7 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 8.4   Max: 40.3
Current: 32.7
8.4
40.3
Price/Tangible Book 8.3
ABMD's Price/Tangible Book is ranked lower than
59% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. ABMD: 8.3 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1.3   Max: 10
Current: 8.3
1.3
10
Price/DCF (Projected) 43.8
ABMD's Price/DCF (Projected) is ranked lower than
57% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. ABMD: 43.8 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 37.3   Max: 37.3
Current: 43.8
Price/Median PS Value 0.9
ABMD's Price/Median PS Value is ranked higher than
68% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. ABMD: 0.9 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.4   Max: 2
Current: 0.9
0.4
2
Price/Graham Number 4.9
ABMD's Price/Graham Number is ranked lower than
61% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ABMD: 4.9 )
ABMD' s 10-Year Price/Graham Number Range
Min: 4.1   Max: 16.3
Current: 4.9
4.1
16.3
Earnings Yield (Greenblatt) 2.20
ABMD's Earnings Yield (Greenblatt) is ranked higher than
62% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ABMD: 2.20 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 2.2
0.1
3.7
Forward Rate of Return (Yacktman) -1.07
ABMD's Forward Rate of Return (Yacktman) is ranked lower than
55% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: -1.07 )
ABMD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.4   Max: -1.2
Current: -1.07
-3.4
-1.2

Business Description

Abiomed, Inc. was incorporated in Delaware. The Company is a provider of mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company's Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. It manufactures and sells the AB5000 Circulatory Support System and the BVS 5000 Biventricular Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company's AbioCor Implantable Replacement Heart is the first completely self-contained artificial heart. Designed to sustain the body's circulation, the AbioCor is intended for end-stage biventricular heart failure patients whose other treatment options have been exhausted. Its main competitors are Getinge, Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, CircuLite, Inc., Terumo Heart, Inc. and CardiacAssist Inc. The healthcare industry, and thus its business, is subject to extensive federal, state, local and foreign regulation.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:AIO.Germany
ยป More Articles for ABMD

Headlines

Articles On GuruFocus.com
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 
Trade Setups for May 17, 2010 May 17 2010 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 05 2010 
ABIOMED Inc. Reports Operating Results (10-Q) Nov 06 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK